Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
Rani Therapeutics filed a shelf registration on Form S-3 to replace its prior registration and may offer up to $200,000,000 of Class A common stock, preferred stock, debt securities and warrants in one or more offerings. The company’s Class A common stock trades on Nasdaq under RANI (last reported sale $0.53 on August 7, 2025) and the prospectus states a public float of approximately $32.9 million based on 47,094,467 shares at $0.698 per share (July 14, 2025). The filing notes prior sales of $3.0 million under General Instruction I.B.6, making Rani currently eligible to offer up to approximately $7.9 million of Class A stock under that instruction.
Operationally, Rani is a clinical-stage biotherapeutics company developing the oral RaniPill platform. The RaniPill GO (up to 3 mg microtablets) completed three Phase 1 trials. A high-capacity RaniPill HC (up to 200 µL liquid payload) has preclinical data with antibodies and a peptide and is intended to enter clinical testing in the second half of 2025. The prospectus reiterates there are no approved products, no product revenue, and discloses forward-looking risk including concerns about the company’s ability to raise capital and substantial doubt regarding its ability to continue as a going concern.
Rani Therapeutics (Nasdaq:RANI) filed an 8-K disclosing receipt of a Nasdaq minimum-bid-price deficiency notice. The stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
The Company has 180 days, until December 17 2025, to lift its bid to at least $1.00 for 10 straight sessions. If unsuccessful, Rani may seek a second 180-day grace period by moving to the Nasdaq Capital Market and, if needed, enacting a reverse stock split. Failure to regain compliance would result in delisting.
Management is monitoring the share price and evaluating alternatives but gives no assurance of success. Liquidity, investor base and valuation could be materially affected if the listing is lost.